News

The NBCD science-team will be present at this year's American College of Rheumatology Convergence on 11-14 November in Philadelphia, USA. Here, they will present the Ignite poster: “Antihistamine Use and Structural Progression of Knee OA: A Post-Hoc Analysis of Two Phase 3 Clinical Trials”.

CCO, Casper Clemmensen, is attending BIO-Europe 2022 in Leipzig these days. With a packed calendar, he is ready to discuss assets within musculoskeletal indications and help drive the development of this important area.

The paper is entitled: "Effect of adrenaline on serum mid-regional pro-atrial natriuretic peptide and central blood volume" and is based on a subgroup of patients from the EFEX-OA-02 study, registered at clinicaltrials.org (registration no. NCT04542668)

The paper is entitled: "An estimate of plasma volume changes following moderate-high intensity running and cycling exercise and adrenaline infusion" and is based on the EFEX-OA-02 trial done in a wide collaboration between NBCD, Sanos Clinic, Rigshospitalet, Nordic Bioscience A/S and KU.

The dedicated science-team from NBCD is attending EULAR these days with a poster, a poster-tour, a publication, and an oral presentation. Our CSO, Asger Bihlet, will be presenting our most recent data, suggesting a role of mast cell inhibition in the treatment of OA, based on data from a large osteoarthritis cohort on June 3rd in Auditorium 15

Sanos Group has entered into an agreement with LEO Pharma to acquire Studies&Me in order to strengthen recruitment for clinical studies, accelerate digital development and contribute to an innovative ecosystem that makes life easier for patients in decentralized clinical studies. The transaction is expected to be completed as of May 1st, 2022.

As a part of our dedication to scientific advancements in the research field of OA, we will be attending the OARSI 2022. We have had 4 research abstracts accepted for presentation, and our CSO Asger Bihlet will be presenting at the OARSI Clinical Trial Symposium on the topic: “The Pain of OA – Deconstruction of Pain and Patient Reported Outcomes (PROs) for the Benefit of Patients and Clinical Trial Design”

The paper is entitled: “Symptomatic and structural benefit of cathepsin K inhibition by MIV-711 in a subgroup with unilateral pain: post-hoc analysis of a randomised phase 2a clinical trial.”

Anders Fæste leads BCG's Health Care practice in the Nordics and brings invaluable experience from the life-science industry. His dual interests in the life sciences industry and commercial topics makes Anders a great fit for Sanos Groups’ ambitious expansion journey.

Our CCO, Casper Clemmensen, will be attending BIO Europe Virtual 2021. He would be happy to meet and discuss advances in the field of OA clinical trial methodology, as well as new data from our internal clinical research projects.